Splash Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Splash Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Splash Study Today - Breaking & Trending Today

177Lu-PNT2002 Significantly Improves rPFS Vs ARPI in Metastatic Castration-Resistant Prostate Cancer

Published: December 20, 2023

Treatment with 177Lu-PNT2002 resulted in a significant improvement in radiographic progression-free survival vs abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer whose disease had progressed on an androgen receptor pathway inhibitor.

Source: onclive.com

Related Topics:

United StatesKim ChiKaplan MeierProstate Cancer Clinical Trials Working GroupLantheus Holdings IncCommon Terminology CriteriaAdverse EventsLantheus HoldingsTreatment With 177lu Pnt2002Patients With Metastatic Castration Resistant Prostate CancerSplash StudyBc Cancer